EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

NCT Number	NCT04141462
Lead Sponsor	Centre Georges Francois Leclerc
Conditions	Cancer, Genetic Predisposition
Enrollment	613 participants
Start Date	2019-10-07
Primary Completion	2028-04-07 (estimated)
Study Completion	2028-04-07 (estimated)
Updated on ClinicalTrials.gov	2026-04-03